CD19 and B-cell non-Hodgkin lymphoma: Taken together, CD19-specific 7 × 19 CAR-T cell, an armored CAR-T, demonstrated a favorable toxicity profile and sustained efficacy for relapsed, refractory B-cell lymphoma, supporting 7 × 19 CAR T cells as a promising treatment strategy for B-cell malignancies.